Explore 3 Stock Ideas & Industry Insights Download Free Report

General News

How Music Licensing (OTC:SONG) and Its Pro Music Rights Unit Fit Into US Performing Rights Licensing

● The company says Pro Music Rights holds about 7.4% of the US market and represents more than 2.5 million works.

Nitish Kishor | 05 October 2026

Why Winvest Group (OTC:WNLV) Pivoted From Film Production Toward Real-World Asset Partnerships

● Winvest announced a Greater Bay Area RWA Incubator partnership and a Kuala Lumpur Southeast Asia base on November 6, 2025.

Nitish Kishor | 05 October 2026

Why Blue Hat Interactive Entertainment Technology (OTC:BHATF) Moved From Gaming Into Commodity Trading

● Blue Hat's closing bid price was $0.10 or less for ten consecutive trading days through March 6, 2026, Nasdaq said.

Nitish Kishor | 05 October 2026

BioMarin (NASDAQ:BMRN) Reports Five-Year Pompe Data for Pombiliti and Opfolda

• BioMarin announced five-year Phase 3 data for Pombiliti and Opfolda in adults with late-onset Pompe disease on Friday.

Nitish Kishor | 04 October 2026

China Resumes Curbs on Fuel Exports, Tightening Strained Global Energy Markets

• China has stopped granting new commercial export permits for diesel, jet fuel and gasoline to wider global markets.

Nitish Kishor | 04 October 2026

Goldman Sachs Buys $220 Million of Shein Shares After Weak Hong Kong Debut

• Goldman Sachs bought 42 million Shein shares worth about $220 million, equal to 13 percent of the initial share float.

Nitish Kishor | 04 October 2026

Trump Says South Korea Deal Includes $8.4 Billion for Oil Recovery; Seoul Disagrees

• Trump said a US trade deal with South Korea includes $8.4 billion for an enhanced oil recovery project.

Nitish Kishor | 04 October 2026

Lilly and Novo Bet on Amylin as the Next Obesity Drug Pathway After GLP-1s

• Lilly's eloralintide combined with tirzepatide produced 23.3 percent average weight loss at 48 weeks, against 14.8 percent for tirzepatide alone.

Nitish Kishor | 04 October 2026

Novartis Signs mRNA Licensing Deal With China's Abogen Worth Up to $7.8 Billion

• Abogen will receive $575 million upfront from Novartis, with potential for $7.2 billion more tied to development and approvals.

Nitish Kishor | 04 October 2026

White House Economist Does Not Expect More Fed Hikes After Jobs Miss

• Chris Phelan said he does not expect another Fed rate hike after the jobs report and coolerInflationdata.

Nitish Kishor | 04 October 2026
Support

Hi! How can we help you today?

Loading…